摘要:
It is intended to provide a cell fusion type vector having replicability with modified protease-dependent tropism. An M gene knockout virus vector encoding a modified F protein, in which the cleavage site of a paramyxovirus F protein has been modified into a sequence cleaved by another protease, is produced. When transferred into cells, this vector replicates genomic RNA carried thereby and thus extends the cell fusion type infection toward adjacent cells depending on the latter protease as described above but does not release any viral particles. Such a vector encoding an F protein cleaved by a protease the activity of which is enhanced due to cancer shows an effect of inhibiting caner growth in vivo.
摘要:
The present invention provides cell fusogenic vectors having replicative ability, whose protease-dependent tropism has been modified. M gene-deficient viral vectors encoding modified F proteins, in which the cleavage site of the F protein of paramyxovirus is modified to be cleaved by different proteases, were produced. In cells transfected with these vectors, the genomic RNA present in the vectors is replicated, and cell fusogenic infection spreads to neighboring cells depending on the presence of other proteases; however, no viral particles are released. The vectors of this invention, encoding the F proteins which are cleaved by proteases whose activity is enhanced in cancer, show cancer growth suppressive effect in vivo .
摘要:
The present invention relates, in general, to attenuated negative-strand RNA viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. The invention also relates to the development and use of IFN-deficient systems for selection of such attenuated viruses. In particular, the invention relates to attenuated influenza viruses having modifications to the NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. The mutant viruses replicate in vivo but demonstrate reduced pathogenicity, and therefore are well suited for live virus vaccines, and pharmaceutical formulations.
摘要:
L'invention concerne une particule analogue à un virus (VLP) contenant un génome à ARN comprenant un domain 3' et un domaine de remplissage entouré d'une enveloppe de protéine M de la rage ou de protéine similaire tuée d'un rhabdovirus ou paramyxovirus ou paramyxovirus pour former un complexe ribonucléoprotéique. La VLP comprend également une enveloppe lipidique de protéine G de la rage ou de protéine similaire tirée d'un rhabdovirus ou paramyxovirus, ainsi qu'une matrice interne de protéine M2 de la rage ou de protéine similaire tirée d'un rhabdovirus ou paramyxovirus. L'invention concerne également un procédé de construction de la VLP ainsi que l'élaboration d'un vaccin destiné au traitement d'infection par le rhabdovirus et le paramyxovirus utilisant les VLP précitées en combinaison avec un adjuvant. Une structure d'ADN pouvant être utilisée dans le procédé ci-dessus mentionné est également décrite.
摘要:
The present invention provides nanoparticles and compositions of various constructs that combine meta-stable viral proteins (e.g., RSV F protein) and self-assembling molecules (e.g., ferritin, HSPs) such that the pre-fusion conformational state of these key viral proteins is preserved (and locked) along with the protein self-assembling into a polyhedral shape, thereby creating nanoparticles that are effective vaccine agents. The invention also provides nanoparticles comprising a viral fusion protein, or fragment or variant thereof, and a self- assembling molecule, and immunogenic and vaccine compositions including the same.
摘要:
Polypeptides and compositions thereof are provided for treating or limiting metapneumovinjs (MPV) infection, as well as methods for designing such polypeptides. In further aspects, methods of using said isolated polypeptides, VLPs or pharmaceutical compositions are provided, which include methods for treating a metapneumovirus (MPV) infection, methods for limiting development of an MPV infection, methods for generating an immune response in a subject, methods for monitoring an MPV-induced disease in a subject and/or monitoring response of the subject to immunization by an MPV vaccine, methods for detecting MPV binding antibodies, methods for producing MPV antibodies, and methods of preventing an MPV infection.